DexCom, Inc. (DXCM) Forecasted to Post Q4 2018 Earnings of $0.03 Per Share
DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at Jefferies Group decreased their Q4 2018 EPS estimates for shares of DexCom in a research report issued to clients and investors on Tuesday. Jefferies Group analyst R. Denhoy now expects that the medical device company will post earnings of $0.03 per share for the quarter, down from their previous forecast of $0.04. Jefferies Group has a “Buy” rating and a $70.00 price objective on the stock.
A number of other research analysts have also recently issued reports on the company. BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 4th. Barclays reissued a “hold” rating and issued a $60.00 target price on shares of DexCom in a research note on Monday, January 8th. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research note on Monday, November 6th. Piper Jaffray Companies set a $60.00 target price on DexCom and gave the company a “buy” rating in a research note on Monday, February 26th. Finally, BMO Capital Markets boosted their target price on DexCom to $74.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $65.97.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, February 27th. The medical device company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. The business had revenue of $221.00 million during the quarter, compared to the consensus estimate of $217.82 million. DexCom had a negative return on equity of 13.99% and a negative net margin of 6.99%.
Several hedge funds have recently bought and sold shares of DXCM. American International Group Inc. acquired a new position in shares of DexCom during the fourth quarter worth about $116,000. Thompson Davis & CO. Inc. acquired a new position in shares of DexCom during the fourth quarter worth about $137,000. Zions Bancorporation boosted its position in shares of DexCom by 36,222.2% during the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after buying an additional 3,260 shares during the period. Toronto Dominion Bank boosted its position in shares of DexCom by 251.0% during the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after buying an additional 2,608 shares during the period. Finally, Marco Investment Management LLC acquired a new position in shares of DexCom during the fourth quarter worth about $201,000.
In other news, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction dated Tuesday, December 26th. The stock was sold at an average price of $56.39, for a total transaction of $92,197.65. Following the completion of the transaction, the executive vice president now directly owns 65,049 shares of the company’s stock, valued at $3,668,113.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the transaction, the insider now directly owns 484,559 shares of the company’s stock, valued at $27,552,024.74. The disclosure for this sale can be found here. Insiders have sold 34,153 shares of company stock valued at $1,953,327 over the last ninety days. 1.70% of the stock is owned by insiders.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.